New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
05:55 EDTSHPG, SHPG, SHPG, SHPG, SHPG, SQNM, SQNM, SQNM, SQNM, SQNM, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PFE, PFE, PKI, PKI, PKI, PKI, PKI, LMNX, LMNX, LMNX, LMNX, LMNX, ILMN, ILMN, ILMN, ILMN, ILMN, HOLX, HOLX, HOLX, HOLX, HOLX, FLDM, FLDM, FLDM, FLDM, FLDM, GOLD, GOLD, GOLD, GOLD, GOLD, ATHN, ATHN, ATHN, ATHN, ATHN, ALXN, ALXN, ALXN, ALXN, ALXN, AFFY, AFFY, AFFY, AFFY, AFFY, A, A, A, A, AAmerican College of Medical Genetics & Genomics to hold annual meeting
ACMG Annual Clinical Genetics Meeting 2013 is being held in Phoenix, Arizona on March 19-23.
News For A;AFFY;ALXN;ATHN;GOLD;FLDM;HOLX;ILMN;LMNX;PKI;PFE;RHHBY;SQNM;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2015
05:27 EDTSHPGShire reports results from three placebo-controlled Phase 2 studies of SHP625
Subscribe for More Information
April 8, 2015
15:19 EDTRHHBYRoche says receives European approval for Avastin plus chemotherapy
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
08:45 EDTFLDMLife Sciences group well positioned heading into Q1 earnings, says Cowen
Cowen said the Life Sciences sector looks well positioned heading into Q1 earnings despite the group outperforming the broader market recently. The firm believes headwinds have intensified and multiples have stretched, but they see the downside risk as limited with upside risk dependent on improving end-market commentary, new products and milestones, and new details on capital deployment. Stocks in the space include Affymetrix (AFFX), Fluidigm (FLDM), GenMark (GNMK), Myriad Genetics (MYGN) and Quidel (QDEL).
April 7, 2015
17:38 EDTALXNAlexion CEO Dr. Leonard Bell retired as of March 31
Dr. Leonard Bell, the principal founder and CEO of Alexion Pharmaceuticals retired from Alexion effective March 31, after serving as CEO for twenty-three years. No severance was paid to Dr. Bell in connection with his retirement. On April 1, Alexion entered into a Consulting Agreement and a Letter Agreement with Dr. Bell. Dr. Bell continues to serve as Alexion's Chairman of the Board of Directors.
12:58 EDTATHNOn The Fly: Midday Wrap
Subscribe for More Information
10:19 EDTATHNHigh option volume stocks
Subscribe for More Information
10:17 EDTATHNathenahealth April volatility increases on wide price movement
athenahealth April weekly call option implied volatility is at 46, April is at 45, May is at 35, June is at 32; compared to its 26-week average of 38 according to Track Data, suggesting decreasing price movement.
10:10 EDTSHPGJazz patent on Xyrem latest to be challenged by Kyle Bass
Subscribe for More Information
09:52 EDTATHNEinhorn reiterates short thesis on athenahealth at conference
Subscribe for More Information
08:10 EDTSHPGShire shares pricing in worst case scenario for patents, says Citigroup
Subscribe for More Information
08:09 EDTPFEPfizer, Merck KGaA finalize agreement to co-promote XALKORI
Merck KGaA (MKGAY) and Pfizer (PFE) announced the finalization of the co-promotion agreement allowing the companies to co-promote Pfizerís anaplastic lymphoma kinase inhibitor XALKORI. Under the agreement, XALKORI will be co-promoted in two waves, the first of which will begin in the second and third quarters of 2015 in the United States, Canada, Japan and five European Union countries: France, Germany, Italy, Spain and the United Kingdom. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, the U.S. and Canadian biopharmaceutical businesses of Merck KGaA. The second wave will begin in 2016 and includes China and Turkey. n 2015, Merck KGaA will receive a reimbursement associated with its promotion of XALKORI, followed by an 80% for Pfizer, 20% for Merck KGaA profit sharing on the product starting in 2016. The co-promotion term will last through December 31, 2020 for the U.S., Canada, Japan, France, Germany, Italy, Spain and the U.K. and from January 1, 2016 through December 31, 2021 in China and Turkey. Pfizer will report the sales of XALKORI in countries where it is co-promoted with Merck KGaA.
07:21 EDTILMNIllumina buy-side expectations may be too high, says UBS
Subscribe for More Information
07:14 EDTRHHBY, PFEEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:13 EDTSHPGShire patent challenges only modest threat, says Jefferies
Subscribe for More Information
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
05:23 EDTSHPGShire reaches agreement with FDA on clear regulatory path for SHP465
Shire announces that it has reached an agreement with the FDA on a clear regulatory path for SHP465, an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder, or ADHD, in adults. Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD. While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The company anticipates the clinical trial's first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then expects to submit to the FDA by 2Q17 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire's announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
April 6, 2015
16:13 EDTLMNXLuminex launches the NxTAG Respiratory Pathogen Panel
Luminex announced the launch of the NxTAG Respiratory Pathogen Panel, RUO. The NxTAG Respiratory Pathogen Panel is the only respiratory assay that enables laboratories to both simultaneously detect 22 respiratory pathogens in a single closed tube system and accommodate the higher throughput required to respond to seasonal changes in demand. "We are excited to bring the RUO version of the NxTAG Respiratory Pathogen Panel to market," said Homi Shamir, President and CEO of Luminex. "Luminex introduced multiplexed respiratory panels to the clinical market in 2008 and our customers are anxiously awaiting a next-generation product that delivers expanded panel coverage and a simple closed tube workflow, combined with the throughput and quality of results established by the xTAG Respiratory Viral Panel. We are also pleased to report that we remain on track with our NxTAG clinical trials schedule which started in the first quarter of the year, and we expect the FDA submission to occur in the summer of 2015."
10:37 EDTPFETargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalystís leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.
09:09 EDTSHPGShire says will defend patents 'vigorously' after Hayman petitions
Subscribe for More Information
08:22 EDTILMNBofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use